Written Grounds -Patents & SPCs

Ex-parte hearing decisions relating to patents, SPCs and SPC Extensions

SPC No.ProductApplicantDecision Date
2015/043Safinamide for use in combination with levodopa/PDI, and optionally with other PD medicinal products, for the treatment of Parkinson's DiseaseNewron Pharmaceuticals S.p.A14/05/2024
2014/038Dapagliflozin and Metformin (XIGDUO)AstraZeneca AB24/05/2021
2017/035Talimogene Iaherparepvec (IMLYGIC)Georgetown University12/04/2021
2019/010Binimetinib and Encorafenib (MEKTOVI/BRAFTOVI)Array BioPharma Inc12/03/2021
2017/044Obinutuzumab and Bendamustine (GAZYVARO)Roche Glycart AG19/01/2021
2009/040Prucalopride (RESOLOR)Shire International GmbH23/08/2019
2013/035Insulin degludec and Insulin aspart (RYZODEG)Novo Nordisk A/S14/01/2019
2014/050Ezetimibe and Rosuvastatin (VIAZET)Merck Sharp & Dohme Corp.03/08/2017
1996/028Losartan potassium (COZAAR)E.I. Du Pont De Nemours & Company23/09/2009
1999/002Valsartan (CO-DIOVAN)Novartis AG10/03/2005

Patents Act, 1992